Prime-boost vaccination using DNA and whole inactivated virus vaccines provides limited protection against virulent feline immunodeficiency virus (Q45410977)

From Wikidata

Jump to navigation Jump to search

scientific article published on 18 July 2006

Language	Label	Description	Also known as
English	Prime-boost vaccination using DNA and whole inactivated virus vaccines provides limited protection against virulent feline immunodeficiency virus	scientific article published on 18 July 2006

Statements

scholarly article

1 reference

Europe PubMed Central

14 December 2017

Prime-boost vaccination using DNA and whole inactivated virus vaccines provides limited protection against virulent feline immunodeficiency virus (English)

1 reference

Europe PubMed Central

14 December 2017

feline immunodeficiency virus

object named as

feline immunodeficiency virus

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

14 December 2017

author name string

Jennifer Bruce

2

1 reference

Europe PubMed Central

14 December 2017

Dieter Klein

3

1 reference

Europe PubMed Central

14 December 2017

J Norman Flynn

4

1 reference

Europe PubMed Central

14 December 2017

Matthew C Golder

5

1 reference

Europe PubMed Central

14 December 2017

Susan MacDonald

6

1 reference

Europe PubMed Central

14 December 2017

Oswald Jarrett

7

1 reference

Europe PubMed Central

14 December 2017

James C Neil

8

1 reference

Europe PubMed Central

14 December 2017

language of work or name

0 references

publication date

18 July 2006

1 reference

Europe PubMed Central

14 December 2017

1 reference

Europe PubMed Central

14 December 2017

24

1 reference

Europe PubMed Central

14 December 2017

49-50

1 reference

Europe PubMed Central

14 December 2017

7095-7108

1 reference

Europe PubMed Central

14 December 2017

Human immunodeficiency virus and AIDS: insights from animal lentiviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

FIV infection of the domestic cat: an animal model for AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

Experimental vaccine protection against feline immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

Dual-subtype FIV vaccine (Fel-O-Vax FIV) protection against a heterologous subtype B FIV isolate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

Protection against feline immunodeficiency virus using replication defective proviral DNA vaccines with feline interleukin-12 and -18.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

Protection against FIV challenge infection by genetic vaccination using minimalistic DNA constructs for FIV env gene and feline IL-12 expression

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

Protective immunity against feline immunodeficiency virus induced by inoculation with vif-deleted proviral DNA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

Vaccination with inactivated virus but not viral DNA reduces virus load following challenge with a heterologous and virulent isolate of feline immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

DNA vaccines against human immunodeficiency virus type 1 in the past decade

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

Factors influencing cellular immune responses to feline immunodeficiency virus induced by DNA vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

Protection by SIV VLP DNA prime/protein boost following mucosal SIV challenge is markedly enhanced by IL-12/GM-CSF co-administration

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

Efficacy evaluation of prime-boost protocol: canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

Feline leukemia virus DNA vaccine efficacy is enhanced by coadministration with interleukin-12 (IL-12) and IL-18 expression vectors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

Development of IL-2 Independent Feline Lymphoid Cell Lines Chronically Infected with Feline Immunodeficiency Virus: Importance for Diagnostic Reagents and Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

Evolution of replication efficiency following infection with a molecularly cloned feline immunodeficiency virus of low virulence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

Serological diagnosis of feline immunodeficiency virus infection based on synthetic peptides from Env glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

Development, characterization, and viral susceptibility of a feline (Felis catus) renal cell line (CRFK).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: reevaluation of neutralizing antibody levels elicited by a protective and a nonprotective vaccine after removal of antisubstrate cell antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

Development of antibodies to feline IFN-gamma as tools to elucidate the cellular immune responses to FeLV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

Involvement of gag- and env-specific cytotoxic T lymphocytes in protective immunity to feline immunodeficiency virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

Establishment of a feline T-lymphoblastoid cell line highly sensitive for replication of feline immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

Accurate estimation of transduction efficiency necessitates a multiplex real-time PCR.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

Assessment of CD4+ and CD8+ IFN-gamma producing cells by ELISPOT in naïve and FIV-infected cats

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

Feline CD8+ cells induced with FIV infected, irradiated T cells produce multiple anti-FIV factors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

Gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: poorer control of a pathogenic viral challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

Potential alterations in immunogenicity by combining or simultaneously administering vaccine components.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

Lymphoid activation: a confounding factor in AIDS vaccine development?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

Use of CD134 as a primary receptor by the feline immunodeficiency virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

Limited efficacy of an inactivated feline immunodeficiency virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

Immunogenicity of an anti-clade B feline immunodeficiency fixed-cell virus vaccine in field cats.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

Dual-subtype vaccine (Fel-O-Vax FIV) protects cats against contact challenge with heterologous subtype B FIV infected cats

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.001

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2006.07.001

1 reference

Europe PubMed Central

14 December 2017

1 reference

Europe PubMed Central

14 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45410977&oldid=2076836812"